Open an account

LeonaBio

LONA · NASDAQ

$5.27+$0.22 (+4.36%)TodayMarket closed ·
Prev close $5.05

About LONA

LeonaBio, Inc. engages in the development of small molecules to restore neuronal health and stop neurodegeneration. The company is headquartered in Bothell, Washington and currently employs 19 full-time employees. The company went IPO on 2020-09-18. The firm's lead drug candidates, lasofoxifene and ATH-1105, are novel, small molecule therapies with the potential to address devastating diseases where current treatment options are limited or ineffective. ATH-1105 is a novel, orally available, brain-penetrant, next-generation small-molecule drug candidate designed to positively modulate the neurotrophic HGF system for potential treatment of neurodegenerative diseases, including ALS, Alzheimer's disease, and Parkinson's disease. Lasofoxifene is a novel, nonsteroidal SERM with a binding profile, designed to confer potent activity against both wild-type and mutant estrogen receptors, including the clinically significant ESR1 mutations.

Employees
19
Headquarters
Bothell, Washington
Listed
Sep 18, 2020
Sector
Health Care
Industry
Pharmaceuticals
Website
leonabio.com

LONA key statistics

Market cap
49.65M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
461.31K
Volume
61.52K
Open price
$5.11
High today
$5.46
Low today
$4.86
52 Week high
$14.21
52 Week low
$2.57

LeonaBio (LONA) at a glance

As of Oct 20, 2026, LeonaBio (LONA) shares are priced at $5.27, giving the company a market cap of 49.65M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $4.86 and $5.46. The current price is 8.4% above the day's low and 3.5% below its high.

Volume so far is 61.52K shares, below the average of 461.31K shares a day.

Over the past year LeonaBio has ranged from $2.57 to $14.21, and now sits 23% of the way up that range.

LeonaBio met or beat analyst EPS estimates in 5 of the last 8 quarters. In Q2 FY26 it reported -$0.80 per share against an estimate of -$1.29.

The average analyst price target is $17.68, 235.5% above the current price, from 3 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 3 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 5 analystsAvg $17.68
Low
$15.15
Now
$5.27
High
$21.00

LONA earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 5 of the last 8 quarters, by 18.3% on average.

  1. Q3 FY24: reported -$7.50 per share against an estimate of -$7.20
  2. Q4 FY24: reported -$3.90 per share against an estimate of -$4.49
  3. Q1 FY25: reported -$2.30 per share against an estimate of -$2.45
  4. Q2 FY25: reported -$1.80 per share against an estimate of -$1.84
  5. Q3 FY25: reported -$1.68 per share against an estimate of -$1.24
  6. Q4 FY25: reported -$3.46 per share against an estimate of -$1.30
  7. Q1 FY26: reported -$1.73 per share against an estimate of -$2.55
  8. Q2 FY26: reported -$0.80 per share against an estimate of -$1.29

LONA news

  • Press releaseGlobe Newswire

    LeonaBio to Participate in Cantor Global Healthcare Conference 2026

Similar companies

Companies in the same industry as LeonaBio

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.